Press releases

Filter by year:

Presentation at American Neurological Association Congress Confirms Potential of GeNeuro’s Novel anti-HERV-K Antibody for Amyotrophic lateral sclerosis

Geneva, Switzerland, 18 October, 2021 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, announced today that the NINDS, part of the U.S. National Institutes of Health (NIH), presented novel pre-clinical results at the American Neurological Association (ANA) annual meeting, October 17-19, confirming in pre-clinical models of ALS the neurotoxic properties of HERV-K ENV, a retroviral envelope protein encoded by a pathogenic member of the HERV-K family of endogenous human retroviruses, and the therapeutic potential of GeNeuro's antibody developed to neutralize HERV-K ENV.

GeNeuro Reports 2021 Half-Year Results and Provides Corporate Update

Geneva, Switzerland, September 29, 2021 at 7:00pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today reported its half-year financial results for the period ending June 30, 2021 and provided a corporate update.

GeNeuro and Northwestern University enter into a research collaboration on HERV-W ENV in long-haul COVID

Geneva, Switzerland, September 24, 2021, 8:00am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis, announces today that it has entered into a research agreement with Northwestern University to further investigate the relationship between HERV-W ENV (W-ENV) and long-COVID neuropsychiatric syndromes.

GeNeuro announces that a first patient having finished the ProTEct-MS study at the Karolinska Institutet’s Academic Specialist Center has entered the study extension

Geneva, Switzerland, September 21, 2021 – 6:30 pm CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced that a first patient having completed its ProTEct-MS study at Karolinska Institutet’s Academic Specialist Center (ASC) in Stockholm, which tests temelimab at monthly doses of 18, 36 and 54 mg/kg in MS patients, has entered the ProTEct-MS extension

GeNeuro: financial information and business update for the second quarter 2021

Geneva, Switzerland, July 23, 2021, 8:00am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today reported on its 2021 second quarter cash position and issued a business update.

GeNeuro announces the publication in Multiple Sclerosis of results from CHANGE-MS and ANGEL-MS studies

Geneva, Switzerland, July 15, 2021 – 08:00am CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical developing new treatments for neurodegenerative diseases, such as multiple sclerosis (MS), today announced publication in Multiple Sclerosis of the safety and efficacy results from its temelimab CHANGE-MS and ANGEL-MS clinical studies.

GeNeuro: successful €6 million private placement

Geneva, Switzerland,  July 13, 2021 – 08:00 CET – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (“MS”), today announced the successful completion of a €6.0 million capital increase with cancellation of the preferential subscription rights through an international private placement only to certain qualified and institutional investors of 1,730,458 new ordinary bearer shares of GeNeuro with a par value of CHF 0.05 each (the “New Shares” and the "Offering", respectively).

GeNeuro presents data supporting pathogenic role of an endogenous retroviral protein (HERV-W ENV) in post-COVID neuropsychiatric syndrome Enters collaboration with the FondaMental Foundation to speed development of diagnostic and therapeutic...

Paris, France and Geneva, Switzerland, July 5, 2021 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), presented new data showing that the neuropsychiatric symptomatology seen in “post-COVID” patients may be due to activation of HERV-W ENV expression in these individuals by SARS-CoV-2, and to its persistence long after the acute COVID phase. These data, presented at the first “Neuro Sciences Psychiatry and Neurology Days” held in Paris, France, on July 1-2, provide a biologic rationale explaining why so many COVID-19 patients develop long-term neurological and psychiatric symptoms. This could open the door for a therapeutic intervention with temelimab targeting HERV-W ENV.

GeNeuro and CIRI Renew Collaboration Agreement and Expand Focus to Post-COVID Syndromes

Geneva, Switzerland, June 24, 2021 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), and the CIRI (International Center for Infectiology Research), in Lyon, France, a world-class research institute against infectious diseases, announced today the signing of an extension to their existing Research Collaboration Agreement.

GeNeuro Announces Approval of all Resolutions Proposed at 2021 Annual General Meeting

Geneva, Switzerland, June 1, 2021 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced that its shareholders have approved all resolutions proposed at its Annual General Meeting (AGM) of May 27, 2021. These included among others:


Results 1-10 of 18      Next Page      Last Page